Unicycive Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Unicycive Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 29% to $675,000. Profit margin reached -4525%. Total operating expenses were $21,449,000.
Profit Margin
| 2019 | 0 | -2.30M | |
|---|---|---|---|
| 2020 | 0 | -2.50M | |
| 2021 | 0 | -10.63M | |
| 2022 | 951K | -18.06M | -1899.47% |
| 2023 | 675K | -30.54M | -4525.04% |
UNCY Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 675K | 951K | 0 | 0 | 0 |
Cost of revenue | 0 | 7K | 1K | 0 | 0 |
Gross profit | 675K | 944K | -1K | 0 | 0 |
Operating exp. | |||||
Research and development | 12.90M | 12.43M | 6.08M | 1.01M | 795K |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 21.44M | 19.00M | 8.97M | 2.02M | 1.96M |
Operating income | -20.77M | -18.05M | -8.97M | -2.02M | -1.96M |
Other income (expenses), net | -9.77M | -6K | -1.04M | -244K | -202K |
Income before tax | -30.54M | -18.05M | -10.01M | -2.26M | -2.16M |
Income tax expense | 0 | 6K | 615K | 244K | 139K |
Net income | -30.54M | -18.06M | -10.63M | -2.50M | -2.30M |
Earnings per share | |||||
Basic EPS | -1.28 | -1.2 | -0.71 | -0.16 | -0.15 |
Diluted EPS | -1.28 | -1.2 | -0.71 | -0.16 | -0.15 |
| Data source | Data source | Data source |